期刊
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
卷 75, 期 3, 页码 273-281出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1365-3083.2011.02662.x
关键词
-
类别
资金
- NCI NIH HHS [R01CA138427, R01 CA138427-02, R01 CA138427] Funding Source: Medline
Studies have revealed that tumour-associated myeloid cells (TAMC) are one of the major sources of IL-10 in tumour-bearing mice. However, the significance of TAMC-derived IL-10 in tumour immunity is poorly understood. Here, we show that IL-10 blockade or IL-10 deficiency reduces the capacity of TAMC in suppressing the proliferation of P1A-specific CD8 T cells. In the spleen, IL-10-deficient and wild-type (WT) mice bearing large tumour burdens have similar TAMC populations. The tumours from IL-10-deficient mice, however, have reduced numbers of TAMC compared with tumours from their WT counterparts. IL-10-/-RAG-2-/- mice also had reduced numbers of TAMC compared with tumours from IL-10+/+RAG-2-/- mice; therefore, the reduction in TAMC in IL-10-deficient tumours was not because of adaptive immune response in tumours. Adoptively transferred tumour antigenspecific CD8 T cells expanded more efficiently within tumours in IL-10-/-RAG-2-/- mice than in tumours from IL-10+/+RAG-2-/- mice. Cytotoxic T lymphocyte adoptive transfer therapy prevented tumour evasion in IL-10-/-RAG-2-/- mice more efficiently than in IL-10+/+RAG-2-/- mice. Thus, IL-10 enhances the accumulation of myeloid cells in tumours, and TAMC-derived IL-10 suppresses the activation and expansion of tumour antigenspecific T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据